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Abstract
Prostate cancer (PCa) is the most common type of cancer found in men and among the leading causes of cancer death in
the western world. In the present study, we compared the individual protein expression patterns from histologically
characterized PCa and the surrounding benign tissue obtained by manual micro dissection using highly sensitive two-
dimensional differential gel electrophoresis (2D-DIGE) coupled with mass spectrometry. Proteomic data revealed 118
protein spots to be differentially expressed in cancer (n=24) compared to benign (n=21) prostate tissue. These spots were
analysed by MALDI-TOF-MS/MS and 79 different proteins were identified. Using principal component analysis we could
clearly separate tumor and normal tissue and two distinct tumor groups based on the protein expression pattern. By using a
systems biology approach, we could map many of these proteins both into major pathways involved in PCa progression as
well as into a group of potential diagnostic and/or prognostic markers. Due to complexity of the highly interconnected
shortest pathway network, the functional sub networks revealed some of the potential candidate biomarker proteins for
further validation. By using a systems biology approach, our study revealed novel proteins and molecular networks with
altered expression in PCa. Further functional validation of individual proteins is ongoing and might provide new insights in
PCa progression potentially leading to the design of novel diagnostic and therapeutic strategies.
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Introduction
Prostate cancer (PCa) is currently the leading cancer among
men in western countries [1]. Autopsy studies have revealed that
approximately 30% of men over the age of 50 years and 80% of
men in their 70s have microscopic evidence of prostate cancer
[2,3]. In the year 2007 in the United States, an estimated 218,890
new cases diagnosed and 27,050 men died of PCa [4]. The (early)
detection rate and thus the incidence of PCa has risen dramatically
due to the introduction of PSA screening. Nonetheless, determi-
nation of serum PSA exhibit some major limitations, as elevated
levels closely correlate with both hyperplasia and cancer.
Two-dimensional gel electrophoresis (2DE), a powerful tool
used for protein separation and expression profiling is one of the
core technologies in proteomics [5,6]. Protein expression analysis
of patient materials are informative led to the identifying cancer
specific markers for diagnosis, therapeutic targets and is the basis
for revealing various cellular events associated with cancer
progression [7]. To date, several research groups have already
performed protein and gene expression profiling studies on
surgical and biopsy PCa specimens [8–12] but most of the
potential reported markers are not in clinical application for
definitive diagnosis of PCa. However, previous studies focussed on
interindividual comparisons of proteomic analysis of radical
prostatectomies from cancer patients to those of non cancer
patients with conventional 2DE. Intraindividual analysis of tumor
and benign tissue samples (adjacent to tumor) from the same
cancer patients may reduce technical variability and thus provide a
means to increase specificity of the results and to increase chances
to identify specific disease-associated protein alterations.
In the present study, we investigated the comparative proteome
of prostate cancer and its adjacent histological benign tissue from
PLoS ONE | www.plosone.org 1 February 2011 | Volume 6 | Issue 2 | e16833cancer patients with definitive pathological characterization in our
2-D differential in-gel electrophoresis (DIGE) system for protein 2-
D electrophoresis [13] and MALDI-TOF-MS/MS for protein
identification. The differentially expressed proteins were analysed
by MetaCore
TM (Gene GO) and Ingenuity Pathway Analysis
program (Ingenuity Systems). The major hubs of significant sub
networks were validated by real-time PCR analysis. Systems
biology network analysis might provide the potential role of
proteins in different regulatory pathways that control PCa
progression and predict new biomarkers, which can be further
validated using Western blotting and immunohistochemical (IHC)
approaches.
Materials and Methods
Clinical Samples and Ethics Statement
Tissue samples and patient data were obtained with informed
written consent. The study was approved by the Ethics
Committee of the University Hospital Hamburg Eppendorf
and carried out in accordance with the declaration of Helsinki.
For protein expression analysis whole prostates were collected
after radical prostatectomy from patients with elevated PSA
values and preoperative pathological examination at Martini
C l i n i c s ,H a m b u r g ,G e r m a n y .P a t i e nts received no preoperative
therapy. 24 patients were selected and the corresponding
clinical and pathological data is provided are in Table 1. The
serum PSA levels of these patients were determined and all
patients had a range between 3.9 and 30.4 ng/ml (mean PSA
value=10.93 ng/ml) and a Gleason score between 3+3a n d4 +5
[14,15].
After radical prostatectomy samples were frozen in liquid
nitrogen until use. Tumor and benign areas were marked on the
sections. We employed manual micro dissection method to obtain
pathologically characterized materials for our proteomics ap-
proach. The corresponding areas on the remaining blocks were
sliced out with sharp knife, embedded in Tissue-tekH and stored at
280uC until use.
Protein isolation and labelling with CyDyes
Tissue was rinsed with physiological saline (0.9% NaCl) to
remove residual mounting materials, marking dye and blood. The
sliced tissues were directly homogenized in DIGE lysis buffer
(30 mM Tris, 2 M Thio urea, 7 M Urea, 4% CHAPS; about
0.5 mL/200 mg tissues). The resulting homogenate was cleared to
remove all debris by centrifugation at 12,000g for 15 min at 4uC,
the protein supernatant was collected and its protein concentration
was determined by a modified Bradford assay [16]. The quality of
the samples for DIGE was evaluated by mini 2DE (7 cm IPG
strips, pH 4–7). The protein lysates were labelled with Cy Dyes
according to the manufacturer’s protocol for minimal labeling
(CyDye DIGE Fluor minimal dyes, GE Healthcare). In order to
minimize dye-specific labeling artifacts, Cy3 and Cy5-labeling
patterns were swapped among the same group of samples. An
internal standard pool with equal amounts of each protein sample
(25 mg) was used to reduce inter-gel variation. The pooled internal
standards were labelled with Cy2. 50 mg protein of each sample
Table 1. List of patients included in the proteomic study together with their PSA levels, histology grading and tumor stage.
S. No Patient No. Tumor satge Gleason Score Pre operative hormone therapy Pre operative PSA
1 T 4850 pT2c 3+4N A N A
2 T 4484 pT2c 3+4N o 8 . 6
3 T 2443 pT2c 3+3N o 7 . 9
4 T 2258 pT2a 3+3N o 3 . 9
5 T 3969 pT3b 4+3 No 30.4
6 T 3972 pT2c 3+4 No 13.77
7 T 2621 pT2c 3+4 No 7.53
8 T 2266 pT2a 3+4 No 5.53
9 T 3455 pT2c 3+3N o 5 . 5
10 T 2620 pT2c 4+3 No 9.51
11 T 4486 pT2c 3+4 No 29.41
12 T 2267 pT3a 3+4N o N A
13 T 3974 pT3a 4+5N o 6 . 3
14 T 2437 pT2c 4+3 No 11.2
15 T 4167 pT3a 3+4 No 5.33
16 T 3132 pT2c 3+4 No 13.56
17 T 2442 pT2c 3+4 No 18.8
18 T 2933 pT2c 4+3 No 7.09
19 T 2259 pT2c 3+4N o 8 . 9
20 T 2936 pT2c 3+4 No 4.19
21 T 2434 pT2c 3+4 No 10.3
22 T 4766 NA NA NA NA
23 T 3982 NA NA NA NA
24 T 36126 NA NA NA NA
doi:10.1371/journal.pone.0016833.t001
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for 30 min. Reaction was quenched/stopped with 10 mM L-lysine
for 10 min under the same conditions.
DIGE-Two-dimensional gel electrophoresis (DIGE-2-DE)
The first dimension isoelectric focussing was carried out by
using 24 cm immobilized pH gradient dry strips (IPG) with a
linear pH 4–7 gradient. For analytical gels, a pair of Cy3 and Cy5
labelled samples (each 50 mg of protein) and 50 mg of Cy2 labelled
internal standard were pooled and filled up to 150 ml with 26
sample buffer (7 M urea, 2 M thiourea, 4% CHAPS, 2% DTT)
supplemented with 2% (v/v) IPG buffer pH 4–7). For rehydration,
dilute samples with 26rehydration buffer (8 M urea, 4% CHAPS,
13 mM DTT) supplemented with 1% (v/v) IPG buffer pH 4–7
and few grains of Bromophenol blue) to final volume of 450 ml.
IPG strips (24 cm, pH 4–7, GE Health Care) were passively
rehydrated overnight at 20uC in IPGPhor cassettes. For
preparative gels, 750 mg of unlabelled protein pooled from equal
amounts of samples was used. Proteins were separated by the
PROTEAN IEF system (Bio-Rad) using a programmed voltage
gradient at 20uC with a current limit of 50 mA per strip in the dark
under the following conditions: 4 h at 250 V, 8000 V linear
gradient to 15000 V hrs, rapid 8000 V to 75000 V hrs, for a total
of 90 kVh. After IEF, the IPG strips were equilibrated in buffer 1
(50 mM Tris-HCl pH 8.8, 8 M urea, 30% glycerol, 2% SDS and
0.5% DTT) and buffer 2 containing 4.5% iodoacetamide instead
of DTT in each case for 15 minutes.
Second dimension was performed in PROTEANH Plus
Dodeca
TM Cell system. The equilibrated strips were applied to
the top of 12.5% SDS-PAGE gels and sealed with 1% agarose
prepared in SDS-Tris-glycine buffer with traces of bromophenol
blue as a tracking dye to monitor electrophoresis. Polyacrylamide
gels (12.5%) were cast in low fluorescence glass plates. Electro-
phoresis was performed with constant voltage (80V) at 20uC until
the dye front reached the bottom of the gel. The complete
apparatus is protected from light. Following electrophoresis,
analytical gel cassettes were washed with ddH2O and wiped with
dust free tissue paper. The Cy2 (internal standard), Cy3 and Cy5
labelled proteins in each gel were visualized by using a Typhoon
9400
TM laser scanner (GE Healthcare) at 100 microns density by
using different excitation and emission wavelengths directly from
gels between glass plates. Optimal excitation/emission wave-
lengths for fluorescence detection are 488/520 nm for Cy2, 532/
580 nm for Cy3, and 633/680 nm for Cy5. Preparative gels were
stained with RotiH-Blue, a colloidal coomassie brilliant blue G250
stain. Briefly, gels were fixed in 40% methanol, 15% acetic acid for
at least 4 hrs and then immersed in colloidal staining solution
overnight. To remove background staining gels were washed in
20% methanol.
Image analysis
Delta 2D differential analysis software version 4.0 (Decodon
GmbH, Germany) was used in this study. For individual gel
analysis, spots were detected, quantified and normalized according
to the volume ratio of corresponding spots detected in the Cy2
image of the pooled-sample internal standard using the internal
standard module. All normalized spot quantities from the gels
were collectively analyzed as two independent groups ‘‘Tumor’’
and ‘‘Benign’’, which enables matching of multiple gel images
from different patients to provide statistical data on average
abundance for each protein spot among the DIGE gels included in
analysis. Three gels from benign group were excluded from
analysis due to the problem in DIGE labelling. Student’s t-test was
performed to assess the statistical significance of differentially
expressed proteins. Based on average spot volume ratio, spots
whose relative expression is changed at least 1.5 fold (increase or
decrease) between benign and tumors at 95% confidence level (t-
test; p,0.05) were considered to be significant. For subsequent
mass spectrometry analysis significant spot coordinates were
transferred to coomassie stained preparative gel for spot picking.
Mass spectrometry
Preparation of peptide mixtures for MALDI-TOF-MS/
MS. Protein identification was performed as described recently
[11]. Briefly, proteins were excised from Colloidal Coomassie
Brilliant Blue stained 2-DE gels using a spot cutter. Digestion with
trypsin and subsequent spotting of peptide solutions onto the
MALDI-targets were performed automatically in the Ettan Spot
Handling Workstation. Gel pieces were washed 50 mM
ammoniumbicarbonate/50% (v/v) methanol and with 75% (v/v)
ACN. After drying trypsin solution containing 20 ng/ml trypsin in
20 mM ammoniumbicarbonate was added and incubated at 37uC
for 120 min. For peptide extraction, gel pieces were covered with
50% (v/v) ACN/0.1% (w/v) TFA and incubated for 30 min at
37uC. The peptide containing supernatant was transferred into a
new micro plate and the extraction was repeated. The
supernatants were pooled and dried completely at 40uC for
220 min. Peptides were dissolved in 0.5% (w/v) TFA/50% (v/v)
ACN and spotted on the MALDI-target. Then, matrix solution
(50% (v/v) ACN/0.5% (w/v) TFA) saturated with CHCA was
added and mixed with the sample solution by aspirating the
mixture five times. Prior to the measurement in the MALDI-TOF
instrument, the samples were allowed to dry on the target 10 to
15 min.
MALDI-TOF-MS. TheMALDI-TOFmeasurementofspotted
peptide solutions was carried out on a 4800 MALDI TOF/
TOF
TM Analyzer. The spectra were recorded in reflector mode
in a mass range from 800 to 4000 Da with an internal one-point-
calibration on the autolytic fragment of trypsin (mono-isotopic
(M+H)
+ m/z at 2211.104, signal/noise $10). Additionally
MALDI-TOF-MS/MS analysis was performed for the 5
strongest peaks of the TOF-spectrum after subtraction of peaks
corresponding to background or trypsin fragments. The internal
calibration was automatically performed as one-point-calibration
if the mono-isotopic arginine (M+H)
+ m/z at 175.119 or lysine
(M+H)
+ m/z at 147.107 reached a signal to noise ratio (S/N) of
at least 5. After calibration a combined database search of MS
and MS/MS measurements was performed using the GPS
Explorer software v3.6 (Applied Biosystems, Foster City, USA).
Peak lists were compared with the SwissProt rel.49 restricted to
human taxonomy or IPI human v3.12 database using the Mascot
search engine 1.9 (Matrix Science Ltd, London, UK). Peptide
mixtures that yielded at least twice a mowse score of at least 56
for SwissProt or at least 59 for IPI database results were regarded
as positive identifications.
Bioinformatics analysis of the proteomic data
The significant differentially expressed proteins and their
respective biological functions or relationships were determined
using the KEGG database (http://www.genome.jp/kegg/) and
Entrez protein database (http://www.ncbi.nlm.nih.gov/sites/
entrez?db=protein) from NCBI. Protein networks for analyzing
shortest pathways between the identified proteins were built by
MetaCore
TM (Gene GO) software and Ingenuity Pathways
Analysis (IPA) program (Ingenuity Systems) for identifying
molecular partners involved in particular disease. A master global
network of all differentially expressed proteins (input objects) was
created according to published literature-based annotations, and
Clinical Proteomics in Prostate Cancer
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to focus on activated experiments and/or pathways. Major hubs
were identified based on the connections and edges with in the
network. The protein expression data was analysed by hierarchical
clustering and partition analysis with R-language to find potential
markers which can classify all samples as tumor and benign with
high certainty. The unsupervised clustering was performed using
Euclidean distance measure and the agglomeration method
‘average’ of the log transformed values of all significant
differentially expressed proteins of 45 samples included in the
analysis set.
Lukk et al. showed that genome-wide differential expression
between tumors and control tissue can be characterized using
principal component analysis (PCA) by means of a malignancy
parameter which characterizes coherent differential expression
patters which are associated with tumor formation. In order to
analyze the impact of co-regulation of protein expression on
biomarker identification, unsupervised PCA has been applied on
the protein expression data (normalized on logarithmic scale), both
from tumor and normal tissue samples. The PCA was performed
in Matlab [The Mathworks Inc, Version 14]. The resulting
principal components of PCA are weighted means of the single
protein expressions, where the weights are automatically identified
such that the main variation of protein expression in the data set
can be explained by the first few principal components.
In order to avoid spurious results from outliers, a two step
approach was applied, where in a first step PCA was applied on
the original data. The outlier detection was applied on the
expressions of the principal components. In the second step the
PCA was performed without the outliers. The resulting expression
values for the stabilized principal components where used for
further analysis. In order to analyze the ratio of information with
respect to differential expression which is represented by the first
three principal components and the residual space, for each
protein the expression values for all tissues, quantified by the
vector xi, where split into two components:
xi~xp,izxr,i
where xp,i is the component of xi which is represented by the first
three principal components of the PCA (S3) and xr,i quantifies the
residual protein expressions in the complementary space CS3
which cannot be represented by the first three principal
components of PCA. In order to check the distribution of
differential expression between both components, for the original
data given by xi, the PCA-based components xp,i, and the residual
Figure 1. Representative 2-DE proteome map of prostate tissue from tumor vs. benign samples. Proteins were resolved by IEF over the
pI range 4–7, followed by 12.5% SDS-PAGE and overlaid by Delta2D. After extraction from tissues, proteins were labeled with Cy3 and Cy5. An internal
standard comprised of equal amount of proteins from all samples (benign and PCa groups) was labeled with Cy2 and included in all gels. The green
spots indicate downregulated proteins, while the red spots indicate upregulated proteins in PCa relative to the corresponding benign tissue. The
identified proteins that showed significantly altered expression in the PCa are indicated with arrows and labeled with the respectives protein IDs.
doi:10.1371/journal.pone.0016833.g001
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between normal and tumor samples has been performed.
RNA isolation and measurements of gene transcripts of
interests by quantitative real time PCR
Quantitative real time PCR for analysis of transcriptional levels
of proteins of interests was performed using SYBR Green as
described previously. Briefly RNA was isolated from the same
biopsies used for proteome analysis using TRIzolH reagent
(Invitrogen, Karlsruhe, Germany) according to the manufacturers’
protocol. The cDNA was prepared by reverse transcription of 1 mg
total RNA using oligo dTprimer (15mer) and M-MLV reverse
transcriptase (Fermentas Life Sciences GmbH, Germany). Quanti
Tect primers for genes of interest GAPDH (housekeeping gene)
were purchased directly from Qiagen, Germany. Primer sets were
shown to generate a single amplicon of the desired size evaluated
by RT PCR followed by agarose gel electrophoresis. Quantitative
real time PCR was performed in thermal cycler (Stratagene,
Germany) using Dynamo Flash SYBR Green qPCR kit (Finn-
zymes, Finland). PCRs for the target and housekeeping genes were
performed in triplicates and mean relative expression levels were
reported. Conditions for real time PCR reaction were as follows: 1
cycle of 94uC for 3 min and 40 cycles of 94uC for 20 s, 60uC for
30 s and 68uC for 30 s. At the end of the PCR, samples were
subjected to a melting analysis to confirm specificity of the
amplicon. To obtain statistical significance data obtained were
analysed by unpaired student t-test performed and p value,0.05
was considered as significant.
Western blotting
Protein extracts were separated by 12% SDS-PAGE and
electrophoretically transferred onto PVDF membrane. Blocking
was carried out in 16Rotiblock solution (Roth Chemicals)
followed by incubating the membrane with primary antibody
overnight at 4uC. Excess antibodies were removed by washing
with NaCl–Tris–Tween 20. Incubation with secondary antibody
conjugated to horseradish peroxidase [anti-(mouse IgG) or anti-
(rabbit IgG), diluted 1:5000 in 16Rotiblock] was performed for
1 h at room temperature. After three washes, the reaction was
developed by the addition of LumiGLO substrate (Thermo). The
emitted light was captured on X-ray film (GE Healthcare).
Results
2D-DIGE Analysis and mass spectrometry
In this study, we were able to establish a standard procedure for
manual micro dissection of radical prostatectomy samples to
obtain pathologically evaluated tumor and benign tissues for
proteome analysis. Furthermore, we analyzed the proteome of
prostates from 24 cancer patients and their corresponding benign
tissue in 21 cases (Table 1) by 2D-DIGE with the pI range of 4.0–
7.0 and molecular weight range between 10 kDa and 120 kDa.
Under these conditions, a total of 1324 spots were clearly detected
and subsequently analysed using Delta2D software for differential
protein expression. 118 spots were significantly altered in their
abundance among all the samples included in the analysis set and
were selected for further identification. The average abundances of
spots were quantified and those with relative changes in
abundance greater than 1.5 times between benign and tumor
(up or down) at 95% confidence level (p,0.05) were considered as
significant. Interesting spots were excised from preparative gels for
protein identification (ID) by tryptic in-gel digestion and MALDI-
TOF MS/MS analysis. Following a Mascot database search using
the acquired MS data 96 spots of 79 proteins were identified as
differentially expressed in cancer compared to benign tissue. The
spots with protein ID are depicted in Figure 1. Individual proteins
were reflected by multiple spots most likely due to posttranslational
modification leading to shifts in the 2-DE. The proteins identified
were grouped into different classes based on functional informa-
tion available. Most of the identified proteins were either
cytoskeletal proteins, enzymes of intermediary metabolisms, signal
transduction, heat shock proteins, tumor-related proteins, oxida-
tive stress related proteins or proteins of unknown function
(Figure 2B). Details of the protein identifications, protein score,
sequence coverage, theoretical pI value and molecular weight as
well as average relative change are shown in Table S1.
Hierarchical clustering and partition analysis of samples
The Figure 2A displays the clustering result. Higher expressions
are coloured red, the lower ones in green. The samples are shown
in columns and the rows indicate proteins. The dendrograms
represent the distances between the clusters. The tumor and
benign samples do not form two distinct separate clusters.
However, hierarchical clustering revealed one group of very
similar tumor samples (10 samples) form a cluster. These samples
were considered as a tumor subgroup in further analysis. Partition
analysis of the expression values resulted in the finding that a single
protein, PPA2 can classify samples with significance (Fisher test
with p-value 6.682e-09). The tumor subgroup was correctly
classified, one (out of 14) of the remaining tumors was misclassified
as benign and three (out of 21) of the benign samples were
misclassified as tumors (data not shown). Partition analysis results
have also shown many proteins can classify all samples correctly
(Data not shown). In an attempt to assign a PSA specific protein
signature, no direct correlation between PSA and differentially
expressed proteins was observed (Data not shown). Taken
together, more than one protein can distinguish all samples as
they were assigned in the groups.
Principal component analysis (PCA)
A 3-dimensional scatterplot of the first three principal
components of the tissue samples shows a good separation
between tumors and normal tissues (Figure 3A). Moreover,
figure 3B, depicting the logarithmic p-values of the original data
xi for each protein on the x-axis and the components xp,i and xr,i
on the y-axis, shows that almost all differential expression can be
reflected by the PCA-based component (red stars).
Apparently the differential protein expression between tumors
and normal tissues cannot be assigned to one individual protein,
but appears to depend on overall protein expression patterns
which are represented by only three components of the PCA, in
accordance to the results described by Lukk et al. [17]. Hence all
(generic, non-redundant) combinations of at least three proteins
which can be measured with high accuracy should be sufficient to
Figure 2. Cluster analysis and Gene Ontology of differential expressed proteins. (A) Unsupervised clustering (euclidean distance measure
and the ‘average’ agglomeration method) was performed using the log transformed expression protein values of 45 samples. The samples are shown
horizontally, the proteins vertically. The dendrograms represent the distances between the clusters. In the upper color bar, the tumor samples are
marked in red, the normal tissues are shown in green. (B) Biological processes regulated by the all significant differentially expressed proteins
assessed by Gene Ontology search and summarized according to their functions.
doi:10.1371/journal.pone.0016833.g002
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PLoS ONE | www.plosone.org 6 February 2011 | Volume 6 | Issue 2 | e16833Figure 3. Principal component analysis can separate normal and tumor tissue. (A) Scatterplot of the first three principal components of
PCA from the protein expression data. The blue stars represent the normal tissues, whereas the red stars show tumors. (B) Distribution of information
with respect to differential expression between tumor and normal tissues. Each cross represents a protein. The p-values in two-sided t-test are
represented by the x-axis, whereas the projections (red: projection onto S3, blue: projection onto complementary space) are represented by the
values on the y-axis. Apparently for all proteins with significant differential expression in the original data (log10(p),22) the differential expression of
Clinical Proteomics in Prostate Cancer
PLoS ONE | www.plosone.org 7 February 2011 | Volume 6 | Issue 2 | e16833establish biomarkers with similar predictive performance, if the
proteins show a significant contribution to the first three principal
components of the PCA. The respective protein set can be selected
according to experimental criteria, non-redundancy and signifi-
cance of correlation to the respective PCA components. Because of
the construction of the principal components of PCA as weighted
means of the expressions of almost all proteins, the principal
components can fill the role of an ‘‘intrinsic noise filter’’. Hence it
is appropriate to express each principal component by the average
expression of a (small) group of proteins in order to benefit from
the intrinsic noise suppression of averaging as well. Figures 3C–D
shows the effect of averaging. The expression of each principal
component has been represented by the average expression of 1–
25 proteins, which have been randomly selected from the set of 38
proteins with highest correlation to each principal component.
Apparently the accuracy and odds ratio depends on the sample
size of the proteins used for representation of the principal
components. The median of the model qualities is in the same size
of the qualities of markers which are based on a biological
rationale, indicating that the differential expression may be
dominated by large scale, strongly co-regulated protein expression
shifts due to tumor formation.
In order to check the expected predictive performance, a logit-
model has been identified using only the first three principal
components of PCA. In cross-validation (leave-one out) the
accuracy of prediction of tumor and normal tissues in the test-
set was 86%. Three (of 21) normal tissues and 3 (of 24) tumor
tissues have been misclassified. The model shows that the tumors
can be split into two groups differing significantly with respect to
their separability from normal tissues (Figure 3E and Table 2).
Statistical tests showed no direct relation of the tumor groups to
the annotated tumor characterizations (Gleason score, PSA
marker etc.). Hence either impact factors aside from protein
expression may contribute to prostate tumor characteristics, or
highly complex, non-monotonic cooperative processes between
the proteins have an impact on tumor status which is not covered
by the principal components of PCA used in the logit regression
model. Functional classification of the 26 identified proteins
the residual component (blue stars) is not significant (log10(p),21), whereas the p-values of the PCA-based components (red stars) are similar to the
original p-values (x-axis). (C–D) Median accuracy and odds ratio of predictive tumor/normal classification. The blue curves show the increase of model
quality by increased sample size used for biomarker model. The red stars show the qualities of the logit model based on the first three principal
components. (E) The output of the regression model (y-axis) indicates the existence of two tumor classes differing significantly according to their
separability. Normal tissues (blue and green boxes) using protein expression.
doi:10.1371/journal.pone.0016833.g003
Table 2. Proteins with significant differential expression between tumor group 1 and tumor group 2 based on PCA.
S.No Gene name Protein name log10(p), 2-sided t-test
1 EIF4A3 Eukaryotic initiation factor 4A-III 29,7068
2 RPSA 40S ribosomal protein SA 28,2847
3 ACTG1 Actin, cytoplasmic 2 28,2063
4 PPP1CA Serine/threonine-protein phosphatase PP1-alpha catalytic subunit 27,9832
5 HSPA5 78 kDa glucose-regulated protein 27,8941
6 HSP90B1 Endoplasmin 27,836
7 EEF1G Elongation factor 1-gamma 27,7305
8 Albu Serum albumin 27,4314
9 TALDO Transaldolase 26,9937
10 CRYL1 Lambda-crystallin homolog 26,917
11 GSTP1 Glutathione S-transferase P 26,7989
12 HSP90AB1 Endoplasmin 26,5476
13 NDRG1 Protein NDRG1 26,1405
14 ACPP Prostatic acid phosphatase 26,0939
15 PDIA3 Protein disulfide-isomerase A3 25,9345
16 PDIA3 Protein disulfide-isomerase A3 25,8639
17 DPYSL2 Dihydropyrimidinase-related protein 2 25,7179
18 PDIA3 Protein disulfide-isomerase A3 25,6059
19 PSMD 26S proteasome non-ATPase regulatory subunit 14 25,5825
20 PPA2 Inorganic pyrophosphatase 2, mitochondrial 25,5641
21 Albu Serum albumin 25,5566
22 NDUFS1 NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial 25,4327
23 C7orf24 Uncharacterized protein C7orf24 25,2732
24 DDAH1 N(G),N(G)-dimethylarginine dimethylaminohydrolase 1 25,2715
25 P4HB Protein disulfide-isomerase 25,1191
26 PGLS 6-phosphogluconolactonase 25,0895
doi:10.1371/journal.pone.0016833.t002
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rized in Figure 4A–C. A total of 70% of the proteins from this
dataset were classified to metabolic processes and more than 60%
were classified to catalytic or binding functions.
Networks analysis of identified proteins in cancer vs.
benign samples
Pathways and networks that involved proteins derived from 2-D
DIGE experimentations differentially expressed in PCa were
analysed using MetaCore
TM, web-based integrative software. The
network architecture represents connections between the individ-
ual proteins (nodes).
In this analysis hubs (key proteins) of protein networks are
proposed to be the key regulatory proteins involved in multicel-
lular processes. The built shortest network (Figure 5A) reveals that
c-Myc, p53, androgen receptor, 14-3-3-epsilon, vimentin, PSA
and estrogen receptor 1 as network hubs. To validate the network,
the highly interconnected hub protein c-Myc mRNA levels
measured from independent set of prostate tissues by real-time
PCR. Results have confirmed overexpression of c-Myc at mRNA
level (Figure 5B) which in turn supports the hypthesis that c-myc
protein levels impact on PCa progression as predicted in network.
However some of the protein objects were not connected to any of
the hubs and shown as unconnected in the network. The
proteomic data is analysed for GeneGo biomarker assessment
and allows matching the input protein list with known disease
profiles consisting of maps, networks and lists of biomarkers known
for a disease. Results revealed that the most of the proteins
predicted markers for prostate cancer (p=9.421E-09) as depicted
in Figure 5C which supports the current data and provide means
to proceed further with validation of unconnected proteins to
identify clinically relevant targets for diagnosis and/or prognosis.
The nodes with high degrees of connectivity are considered to
be the most important components of a network [18] and due to
the high complexity of the network, we analyzed the shortest
directed paths using the shortest pathways algorithm and we
examined hubs with highest significance.
The functional sub networks were built using MetaCore
TM and
Ingenuity Pathway Analysis tool from the input proteins as root
nodes (Network statistics and Gene Ontology processes are
summarized in Table S2. Sub network figures from MetaCore
TM
analysis were not shown). The most significant sub networks
derived from 50 nodes with AR, SRF and TMPRSS2 as network
hubs involving tumor suppressor proteins UCHL1, NDRG1 and
Par-4. This network may be associated with androgen receptor
signalling pathway and cell differentiation. Especially TMPRSS2
fuses with ERG and Ets family genes such as ETV1, ETV4 and
ETV5 in prostate cancers.
The next significant sub network involves many known proteins
to be associated with PCa which may also provide new target
proteins which need to be characterized further. This network is
probably involved in apoptosis, protein metabolic processes and
Ca
2+ signalling pathways. The sub networks derived from the
proteomic data using Ingenuity Pathway Analysis have many
common proteins connected with the important hubs such as AR,
c-Myc, ERS1, Akt/PKB and their role in PCa progression or
potential as disease markers is not known yet (Figure 6A–D).
Protein network analysis and clustering of differentially expressed
proteins revealed new targets such as DDAH1, ARG2, EIF4A3,
Par4, PPA2, Prdx3 and Prdx4, which need further validation to
define their potential application in clinical relevance in prostate
cancer.
Confirmation of differentially expressed proteins in PCa
In order, to further validate highlighted proteins as described in
the previous sections may be useful diagnostic markers and to
confirm the 2D-DIGE results and their transcriptional regulation,
Western Blot and real-time PCR analysis was performed. The 2-
DE protein profile of DDAH1, ARG2, eIF4A3, PPA2, Par-4,
Prdx3 and 4 reveals increase in their abundance in PCa patients.
Validation of these proteins by Western blotting confirmed
significant dysregulation of eIF4A3, ARG2, DDAH1, Par4, Prdx3
and 4 in 79%, 70.1%, 75%, 50.5%, 79%, 70% respectively of
tumors compared to corresponding benign tissues included in
proteomic study; only one representative blot was shown in
Figure 7. The real time PCR results showed significant increase of
amount of mRNA for PPA2, Prdx4 and FKBP4 (Figure 8A–C).
For DDAH1, ARGI2, eIF4A3, PRDX3 and Par4 results have not
Figure 4. Functional classification of differential expressed proteins in different tumor groups. (A) The biological processes, (B)
molecular functions and (C) cellular compartments regulated by the differentially expressed proteins between both tumor groups assessed by Gene
Ontology search.
doi:10.1371/journal.pone.0016833.g004
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tumor compared to benign tissues (Data not shown). Taken
together, this study confirmed the differential regulation of some of
the novel proteins at transcription and/or translational levels in
PCa.
Discussion
The low sensitivity and specificity of current diagnostic methods
for prostate cancer underscores the need for improvement in this
area. Histological investigation is usually performed on multiple
biopsies to distinguish between benign prostate hyperplasia and
prostate cancer. In this study, we focused on proteomic analysis of
pathological characterized tissue specimens to identify new
biomarkers which distinguish PCa from benign prostate tissue.
Previously, conventional 2D gel based proteomic studies on PCa
identified a large number of differentially expressed proteins and
some were reported as potential markers for diagnosis of localized
PCa [11,19–22] but none of these markers have yet been
introduced into clinical practice. As a limitation, many of the
previous studies have been carried to investigate protein
expression patterns between tumor and benign tissue from healthy
controls. Here, we collected cancer and benign tissues from the
same individual prostate gland by manual dissection of frozen
tissue for proteome profiling to avoid inter individual differential
expression of proteins. Moreover, compared to conventional 2DE,
Figure 5. Protein network of differentially expressed proteins in PCa. (A) GeneGO MetaCore
TM was used to generate a network of direct
connections between all identified proteins with altered expression. Red, green, and gray arrows indicate negative, positive, and unspecified effects,
respectively. Many of the identified proteins mapped to AR, p53 and c-Myc pathways involved in PCa progression where as some proteins were not
connected in network. (B) To validate major hubs of the network c-Myc expression at transcriptional level assed by real time PCR from an
independent set of samples. Results showed significant increase in the amount of c-Myc mRNA suggests it may have direct/indirect regulation of its
connected proteins of shortest network. (C) Enrichment of GeneGo diseases by topologically significant proteins identified using all differentially
expressed proteins. Data represents differentially expressed proteins mapped to prostatic neoplasms with highest significance followed by male
genital neoplasms.
doi:10.1371/journal.pone.0016833.g005
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advantages such as higher sensitivity, reproducibility with linear
dynamic range for better quantitation, and less technical variations
because of a pooled control as internal standard. In the current
study, with the ascendancy of manual micro dissection of the
prostatectomy specimens and 2D-DIGE gel-based proteomics we
focussed to identify novel clinically relevant proteins in PCa.
Our proteomic data on prostate material showed differential
expression of 79 proteins in cancer compared to benign tissue.
Gene Ontology (GO) search for biological processes classified
these proteins to HSP family proteins, signal transmitting proteins,
metabolic enzymes, tumor associated proteins, cytoskeletal and
oxidative stress controlling proteins involved in tumor progression
and dissemination. The list includes many proteins known to be
differentially expressed in PCa. As a proof of principle, we found
PAPP, a known marker protein for prostate cancer [23] to be up
regulated in all PCa samples included in this study. The clustering
of samples based on protein expression data did not lead to clusters
separating benign from tumor specimen but rather identified a
subpopulation of samples that formed a unique cluster. Further
data analysis with partition algorithms to find a protein signature
which can classify all samples with high certainty revealed more
than one protein required in order to define sample identity.
Among them, PPA2 is in line with a recent report on its potential
as a marker for metastasis of PCa [24]. In order to analyze the
impact of co-regulation of protein expression on biomarker
identification, unsupervised principal component analysis (PCA)
has been applied on the protein expression data (normalized on
logarithmic scale), both from tumor and normal tissue samples.
Here, in contrast to the cluster analysis we could detect a clear
separation of tumor from normal tissue and a separation of two
distinct tumor groups based on the individual protein expression
patterns found.
In contrast to the cluster analysis, which aims to identify protein
groups which show high co-regulation inside a group, but no co-
regulation between different groups, PCA is focussed on the
representation of the overall variations in the data without any
grouping of proteins. Hence, PCA gives good performance in
classification of phenotypes with high degree of co-regulated
differential expression including various functionalities, in contrast
to cluster analysis which is superior if only a few pathways or
functionalities are differentially regulated between two phenotypes.
Figure 6. Protein subnetworks of differentially expressed proteins in PCa. (A–D) Protein-protein physical/functional interaction sub
networks generated by Ingenuity Pathway Analysis tool. Grey filled boxes are the differentially expressed proteins. Only significant sub networks were
shown in the figure.
doi:10.1371/journal.pone.0016833.g006
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ach as presented here can optimize the information retrieval from
the data.
In order to put our proteomics data in a biological context, we used
a systems biology approach (the platform of specific disease related
proteins networks based on the available data bases) as a rational
strategy for the identification of novel specific markers and new
therapeutic targets. The applicability of the systems biology platform
as an approach to biomarker discovery is supported by several
observations [25]. The data obtained with 2D-DIGE from prostate
tissues was uploaded into MetaCore
TM pathways analysis software.
MetaCore
TM generates an interaction network among the identified
proteins and the rest of the protein objects showing physical or
functional interactions (e.g., inhibition, activation, modification). The
complex network data demonstrates a high number of interactions
between differentially expressed proteins and various signalling
proteins. Interestingly, there are 4 central hubs including c-Myc,
p53, AR and PSAin the network withmultiple connectionstotherest
of the network. These hubs are known to be involved in key cellular
processes or have been identified as potential targets in PCa [26–30].
To validate the resulting network, our real time PCR results
confirmed c-Myc over expression in all samples of this study
(Figure 4B). Therefore, c-Myc may be involved in dysregulation of
the identified proteins in 2D-DIGE coupled mass spectrometry.
Further assessment of the network for biomarker discovery and its
assignment to disease entities in MetaCore
TM platform significantly
scored for prostate cancer. These prediction results together
confirmed that the established differentially expressed proteome
profile matches with the available database.
When complete proteomic data is analysed for pathway mining
the resulting network is highly complex. This led to difficulties in
Figure 7. Western blot analysis of DDAH1, ARG2, eIF4A3,
Prdx3, Prdx4 and PAWR in benign and PCa tissues. Protein
expression identified by western blotting and only representative blots
were shown here. The protein expression levels of the analysed target
proteins have shown their over expression in PCa compared to normal
tissue. GAPDH was used as an internal loading control.
doi:10.1371/journal.pone.0016833.g007
Figure 8. Expression of several protein candidates is regulated
at transcriptional level. Quantitative reverse transcription-PCR of
transcripts (A) FKBP4, (B) Prdx4 and (C) PPA2 shown from benign
prostate tissue (black bars) and localized prostate cancer (grey bars). For
statistical significance unpaired student t-test performed at 95% CI and
p value,0.05 was considered as significant.
doi:10.1371/journal.pone.0016833.g008
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Therefore, we built functional sub networks from the significant
hubs of main network using IPA software. These sub networks
revealed new proteins of unknown function in PCa to be validated
as potential biomarkers. However, their precise role in tumor
genesis needs to be investigated.
In our study the pathway analysis performed with proteomic
data has been interpreted by a theoretical approach that is based
on a predetermined database. However, despite its limitations, we
strongly believe that this rational strategy will help us to identify
candidate biomarkers and proteins that will eventually be
validated further as a potential drug targets for prostate cancer.
From pathway analysis, we selected potential candidate proteins
for further confirmation of their differential expression. Consistent
with our 2D-DIGE proteomic data, the validation by western
results demonstrated overexpression of eIF4A3, DDAH1, ARG2,
Prdx3, and Prdx4 in significantly high percentage of PCa tissues
compared to corresponding benign samples (% of tumors showing
differential expression of each protein described in results section).
Eukaryotic initiation factor 4A-III (eIF4A3) is a member of the
DEAD box protein family implicated to be involved in various cellular
processes such as translation initiation, splicing, ribosome assembly and
mRNA export [31]. Based on cDNA microarrays differential
expression of eIF4A3 in gastric cancer tissues has been reported [32].
As our data showed over expression of ARG2 in PCa, it is
important to note that the protein is also altered in other cancer
tissues such as small cell lung cancer where its expression is
correlated with the dissemination of cancer cells [33]. ARG2 is
known to be involved in polyamine metabolism and polyamines
such as ornithine, spermine and spermidine play a critical role in
prostate cancer development [34]. ARG2 catalyses the conversion
of arginine to ornithine, which is a precursor for the synthesis of
polyamines that control growth of benign and tumor cells of the
prostate [35]. Previous studies have shown the expression of
ARG2 in prostate cancer cell lines and its functional role in
prostate cancer development [36,37].
Two peroxiredoxins such as Prdx3 and Prdx4 are upregulated in
PCa determined by expression analysis. Peroxiredoxins are a family
of multifunctional antioxidant thioredoxin-dependent peroxidases
which have been identified as being differentially expressed in a
variety of neoplasms [38]. Oxidative stress by excess production of
ROS is involved in activation of signal transduction pathways that
are associated with cancer progression [39,40] [41]. In addition to
their role as antioxidative agents, peroxiredoxins are also involved in
multi cellular processes such as cell proliferation, apoptosis and gene
expression [42]. A previous report described that both Prdx3 and 4
have been associated with the presence of hormone receptors in
breast cancer patients [43]. Since prostate tumors are also hormone
dependent, we speculate on a role of Prdx3 and 4 controlling tumor
proliferation, apoptosis and dissemination of tumor cells during
prostate cancer progression. FKBP4 is a peptidyl-prolyl cis-trans-
isomerase significantly overexpressed in PCa. Earlier reports
described its precise role in tumor initiation and progression via
translocation of p53 to the nucleus, leads to p53 inactivation [44]. It
is also known as partner involved in AR signalling described as
therapeutic target for PCa treatment [45].
Dimethylarginine Dimethyl AminoHydrolase 1 (DDAH1) is
known to be involved in NO signalling in cardiovascular disease
and pulmonary hypertension. DDAH1 metabolizes dimethyl
arginines which act as endogenous inhibitors of nitric oxide
synthase (NOS). A recent report suggesting that the intracellular
NO promotes androgen independent growth of prostate cancer
cells highlights its potential contribution for cancer progression
[46]. Moreover, our functional sub network showed connectivity
between p53 and the NOS pathway involving DDAH1. However,
non-enzymatic activities of DDAH1 are not yet known.
In conclusion, the current study identified potential novel
biomarkers for prostate cancer development and/or progression
such as eIF4A3, DDAH1, ARG2, Prdx3, and Prdx4 from
proteomic data using systems biology approach. Functional
validation of these targets will further substantiate their role in
the pathophysiology of prostate carcinogenesis and/or as thera-
peutic targets. Prospective clinical studies will have to confirm
their contribution to clinical prostate cancer management as
potential prognostic and or predictive biomarkers.
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